The global kidney cancer drug market is estimated to reach by USD 4.5 billion at a CAGR of 6.2% till 2022. Kidney is the most important organ in human body. They regulate the blood pressure and serve homeostatic function for maintaining the nutrients and toxins balance in the body of human. They serve as a natural filters of blood, and removes the water soluble wastes and reabsorbing the essential elements from the blood. Since they perform such crucial role, they need constant regeneration of dead nephrons and proper circulation of blood to maintain healthy cell growth due to which kidney are vulnerable to cancerous tumors and metastasis. Renal cell carcinoma which is most common type of renal cancer is toughest to get treated and mainly in advanced stages. In early years 1980’s the treatment for renal cancer was done by removing the kidneys by surgery. Later it gets progressed by removal of the part of the kidney which is affected by tumor and is known as laparoscopic. Kidney cancer drug are normally given to the patients who has reached to stage four renal cell carcinoma. Nowadays different mechanism is being performed for the treatment of cancer due to approved drugs for renal cancer. Some of these drugs are vascular endothelial growth factor inhibitor, cytokine therapy, angiogenesis inhibitor and immune modulation therapy. The major reason for kidney cancer is von hippellindau (VHL) syndrome, smoking, obesity, high blood pressure, occupational exposure, long term dialysis. The symptoms of renal cancer include blood in the urine, getting lump or mass in sides or abdomen, weight loss, lethargy and fever.
Rising prevalence of lifestyle tempted diseases such as excess of drinking and smoking along with chronic diseases such as cancer and renal tumor are some of the major factor which is responsible for driving the market of kidney cancer drug. Along with this, rising geriatric population is also impacting the market positively as the people of this age group are more likely to have chronic diseases. Additionally, the renal cancer drug is preferred by clinicians and patients over therapies. The cancer drugs are life long term treatment regiments which are available for patients who are suffering from advanced stage of metastatic tumor.
The mergers, acquisition and expansions made by the companies are the key strategy which is adopted to boost the kidney cancer drug market. Several approvals which are getting received for the kidney cancer drugs globally are also a prime factor for fueling the growth of kidney cancer drug market.
The market includes several driving factors for it, but although there are some of the challenges which are faced by kidney cancer drug market such as rising preference of consumer for geriatric drugs is negatively impacting the market. In addition, high prices for branded drugs are responsible for hampering the growth of the market of kidney cancer drug.
The kidney cancer drug market is segmented on the basis of type, on the basis of brand, and on the basis of geography. On the basis of type the kidney cancer drug is sub segmented in to clear cell, papillary (type 1 and type 2), chromophobe, oncocytic, and collecting duct. On the basis of brand the kidney cancer drug market is sub segmented in to nexavar (sorafenib), sutent (sunitinib), afinitor(Everolimus), votrient (pazopanib) , Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), and Proleukin (Aldesleukin).
On the basis of the geography the kidney cancer drug market is mainly segmented into North America, Latin America, Europe, APAC and the rest of the world. North America has the largest market share for kidney cancer drug globally. Increase in kidney diseases and kidney cancer are responsible mainly for the driving the market growth in this region.
However Asia pacific is also foreseen to have most effective growth during the forecast period. Rising level of patient awareness, lower cost production of drugs and increasing patients suffering from kidney diseases such as kidney cell carcinoma are estimated to drive the market growth in this region during the forecast period.
The major key players in kidney cancer drug market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Onyx Pharmaceuticals Inc. (US), Bayer AG (Germany), Active Biotech AB (Sweden), Novartis AG (Switzerland), Amgen (US), Genentech, Inc. (US), and Cipla Limited (India). In these market expansions, mergers and acquisition are some of the key strategies adopted by the companies to sustain in the long run. Further, growing need kidney cancer drugsupply across numerous regions is instigating manufacturers for improvising the quality in all aspects of production and distribution.
In January 2016, Novartis AG had unlicensed agreement collaboration with Surface oncology to grow immune-oncology pipeline.
